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CARDIOVASCULAR MEDICINES 

THROMBOLYTICS 

Marise Gatt, Herbert Felice, Dean Harron 
INTRODUCTION 
Thrombolytic therapy represents a major 
advance in reducing mortality following 
myocardial infarction. Phannacist<; must 
be aware of the principles and problems 
of thrombolysis and the large studies 
conducted in hospital and now in the 
community. 
HEMOSTASIS 
When a small vessel is cut and damaged 
the injury initiates a series of events that 
leads to the formation of a clOL The initial 
event is constriction of the vessel, followed 
by the formation of a platelet plug. The 
platelets adhere to exposed collagen and 
liberate serotonin and adenosine 
diphosphate (ADP); this attracts other 
platelets etc. This is formed into a 
defInitive clot by fibrin, which involves a 
cascade of reactions (Fig. I ). Potential 
clotting inside vessels and the breaking 
down of clots so formed are controlled by 
a number of limiting reactions; 
(1) Formation from octivated factor X of 
an antithrombin (antithrombin Ill) and 
the removal of some activated clotting 
factors from the airculation by the liver; 
(2) Thromboxane A2 which promotes 
platelet aggregation and hence clotting, is 
in dynamic equilibrium with the 
simultaneous formation of prostacyclin 
which inhibits aggregation; and 
(3) The fIbrinolytic system that limit') 
clotting. 
The octive component of the fIbrinolytic 
system is plasmin which lyses fIbrin and 
fibrinogen with the formation of 
degradation products which in turn inhibit 
thrombin. 
Plasmin is formed from the inactive 
plasminogen by the action of thmmbin 
in the presence of pla<;minogcn octivators 
,md activator inhibitors (PAl-I). The 
lysis of fibrin by plasmin is held in check 
by alpha 2 ,mtipla<;min. 
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Figure 1 Scherrultic diagram of the coagulation 
{".l1scatie (adapted from Guyen 1951). 
DRUGS WHICH INHIBIT 

CLOTTING AND/OR 

BREAKDOWN THROMBII 

Heparin is a potent anti-coagulant, 
normally found in the body, which acts 
by preventing the octivation of factor IX 
and by activating a platelet factor that 
inhibit'> the oction of thrombin. It also 
increases the negativity of blood vessel 
walls and helps prevent thrombus 
formation (due to it'> structure). Also 
included in this group of parenteral 
anticoagulants are epoprostenol 
(prostacyclin anti platelet activity) and 
ancrod, an enzymatic principle derived 
from the venom of the Malaysian pit­
viper. 
With regards to warfarin before relca<;e 
from the liver into the blood stream, the 
Vitcunin K-depcndent coagulation factors 
(prothrombin, VII, IX and X) are converted 
to a functional group by the addition of an 
extra C<1fboxyVgroup to a glutamic acid 
residuc. In the presence of warfarin, the 
coagulation factors arc released from the 
liver in their unconverted form and hence 
inhibit coagulation. Other oral 
anticoagulants include phenindione and 
protcunine sulphate. Although this latter 
compowld is normally used to counteract 
heparin overdose, when in excess, it has 
an anticoagulant effect. 
The platelet-aggregation inhibiting effects 
of a<;pirin result from its ability to acetylate 
and irreversibly inhibit platelet 
cyc1ooxygenase, thereby reducing the 
formation of thromboxone A2. Its effects 
on thc synthesis of prostacyclin is less 
marked at low doses (1). Also in this 
group is dipyridamole. 
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Figure 2 Activation oJ plasminogen to plasmin (adapted from Sherry /988). 
Pla<;ll1inogen activators (sce list below) 
act by converting the inert pro-enzyme 
plasminogen, into its protcolytically active 
fonn plasmin. 
This laocr group of drugs is now widely 
used ,L<; thrombolytic therapy following 
acute myocardial infarction. The rationale 
is that reperfusion will retard myocardial 
necrosis, reduce infarct size and possibly 
maintain ventricular function and hence 
enhance patient survival. Other uses may 
include · pulmonary embolus, dcep vein 
thrombosis, p;ripheral arterial thrombosis 
and local instillation into occluded shunts, 
e.g. in renal dialysis patients or restoring 
potency in occluded central venous 
catheters. 
THROMBOLYI'IC AGENTS AND 
THEIR MECHANISMS OFACTION 
There are now 6 agents being used or 
evaluated for the lysis of thrombi 
following myocardial infarction. These 
are ­
(a) Indirect acting 
(I) 	 Streptokinase (SK). 
(2) 	 Anisoylatcd pla<;minogen ­
streptokinase activator complex 
(APSAC). 
(b) Directly acting 
(3) 	 Urokinase (UK). 
(4) 	 Recombinant single stranded 
tissue-type plasminogen 
activator (r t-PA, one chain). 
(5) 	 Recombinant prourokinase 
(r pro UK or r scu-PK). 
(6) 	 Recombinant double stranded 
tissue-type plasminogen 
activator (rt-PA, 2 chain). 
The compounds act indirectly/directly to 
activate pla<;minogen (2); this involves 
splitting of the arg560-val561 band in 
plasminogen, which exposes the serine 
protease enzyme centre of plasmin (Fig.2). 
Plasmin is a non-specific proteolytic 
enzyme which derives its fibrinolytic 
prop;rties by the binding of pla<;minogen 
to fibrin during clotting and also by the 
binding of endogenous t-PA to fibrin in 
close proximity to plasminogen following 
its release locally from endothelial cells. 
A<; a result, plasmin fonnation is facilitated 
on the fibrin surface and is indep;ndent of 
the various mechanisms governing and 
regulating pla,minogen activation in the 
systemic circulation (2). 
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Figure 3 Sclwmatic represenlation oJ the rrIDlemlar structure oJ APSAC (Permi~~ion Jrom Beecham). 
The hallmark of physiological fibrinolysis 
is its specificity, by contrdst therap;utic 
thrombolysis, even by the newer 
activators, is accompanied by non-specific 
proteolysis which may have untoward 
effects. The aim of theTaIXutic fibrinolysis 
is the selective activation of plasminogen 
associated with fibrin, while sparing the 
plasminogen in the surrounding blood 
(i.e. fibrin specificity). This occurs with 
the natural plasminogen activators of 
blood, t-P A and pro-UK. However if 
infused at high doses which are necessary 
for effective thrombolysis in patients with 
coronary thrombosis, non-specific 
plasminogen activation takes place(2). 
STREPTOKINASE 
This is a bacterial protein (from cultures 
of Group C beta- haemolytic streptococci) 
that reacts on a one-to-{)ne basis with 
human plasminogen forming a 
streptokinase-plasminogen complex 
which activates the fibrinolytic 
mechanism. As streptokinase is a foreign 
protein it is antigenic. 
Apsac (Anisoylatcd derivative of the Lys­
plasminogen streptokinase) 
This is a complex of human lys­
pla<;minogen and streptokinase in which 
a para-anisoyl group has been added to 
the catalytic centre of the enzyme complex 
(Figure 3). 
In aqucous media, including blood, the 
anisoyl group is removed by hydrolytic 
deacylation. The kringles on the complex 
are the molecular elements which bind to 
the fibrin that holds together the thrombus. 
This binding capacity is increase6 170 
times by using the lys71 plasminogen 
rather than the glu-fonn which circulates 
in the bloodstream (Figure 4) - (fibrin 
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Figure 4· Calalylic efficiency of APSAC. (Permi.~\'ion from Beecham). 
enhancement factor). The value of the 
para-anisoyl group is that it protects the 
catalytic centre of the enzyme and acts as 
a possible pro- drug for its fibrolytic 
activity. Advantages of this include a 
gradual onset on action following a 4-5 
min injection and hence possibly avoiding 
hypotension. It also prolongs APSACs 
duration of action. Antigenicity occurs-­
with APSAC. 
UROKINASE 
This is the first of the naturally occurring 
and direct plasminogen activators (can 
stimulate plasmin formation without first 
forming an activator complex). Currently 
it is being produced by growing hwnan 
foetal kidney cells in tissue culture. (It is 
not antigenic). 
rt-PA 
Tissue plasminogen activator is released 
under physiological conditions from 
various tissue cells. The preparation of 
this highly clot selective type of activator 
has utilized recombinant DNA 
technology. Its preparation has involved 
the transfer of genetic material from a t­
PA producing cell line (originally a 
melanoma) to a Chinese hamster ovarian 
cell line. rt-PA is not antigenic. 
r-pro-UROKINASE 
This is a highly clot selective single chain 
urokinase, which, like t-PA is released 
from various tissue cells under 
physiological conditions. It has been 
suggested a<; having a different mechanism 
of action than t-PA, in that it is thought 
that pro-urokinase only activates lys­
plasminogen (the type bound to fibrin) 
and not glu-plasminogen (the plasma 
form) and this is the basis for its clot 
sensItIvIty. It is being produced 
-commercially by recombinant DNA 
technology by transfer of the cyclic DNA 
from a hwnan tumour source to a non­
hwnan cell line. As with urokinase and 
rt-PA it is not antigenic. 
COMPARISONS BETWEEN 
THROMBOLYTIC AGENTS 
Plasminogen activation in the plasma, 
and the 'fibrin- enhancement' of its effect 
associated with the thrombus platelets 
and endothelial cells varies between 
drugs (Table 1), although as stated 
earlier at therapeutic thrombolytic 
doses differentiation disappears. 
Pharmaceutical aRd pharmacokinetic 
differences are shown in Table 2. They 
indicate that tl/2 plasma elimination half 
lives range from 90 min for APSAC, with 
a very short infusion of 5 min compared 
with a 5 min tl/2 for rt-PA; an infusion of 
180 mins is required for its therapeutic 
effect The clinical profIles demonstration 
reperfusion in 65-70% of patients if treated 
in three hours with re--occlusion occurring 
in 10--20% of patients (Table 3). 
CLINICAL EVALUATION OF 
THROMBOLYTICS IN AcurE 
MYOCARDIAL INFARCTIO(AMl) 
The clinical evaluation of thrombolytics 
in AMI has been marked by a nwnbcr of 
major well conducted placebo controlled 
trials. 
STREPTOKINASE 
ISIS-2 (Second International Study of 
Infarct Survival) (3). In this study, 17,187 
patients entering 417 hospitals up to 24 
hours (median 5 hours) after the onset of 
acute myocardial infarction were 
randomised with a placebo control, 
between ­
(1) a I-hour i.v. infusion of 1.5 million 
units of streptokinase (SK), 
(2) one month 	of 160 mglday enteric 
coated aspirin (ASA), 
(3) both active treatments (SK and ASA), 
(4) neither. 
The results indicated that both SK and 
ASA alone produced a significant 
reduction in 5 week vascular mortality. 
SK 791/8592 (9.2%) vs 
placebo 1029/8595 
(12.0%) (25% reduction) 
ASA 804/8587 (9.4%) vs 
placebo 1016/8600 
(11.8%) (23% reduction) 
SK + ASA 343/4292 (8.0%) vs neither 
568/4300 (13.2%) 
(42% reduction) 
There was evidence of benefit from each 
agent even for patients treated late after 
pain onset Adverse effects associated 
with SK were an excess of bleeds requiring 
transfusion (0.5% vs 0.2%) and of 
confirmed cerebral haemorrhage (0.1% 
vs 0.0%) but with fewer other strokes 
(0.6% vs 0.8%). 
Aspirin significantly reduced non-fatal 
reinfarction (1.0% vs 2.0%) and non-fatal 
strokes (0.3% vs 0.6%) and wa<; not 
associated with any significant increase 
in cerebral haemorrhage or in bleeds 
requiring transfusion. An excess of non­
fatal reinfarction was reported with SK 
when used alone, but not in combination 
with ASA. Those given both had 
significantly fewer reinfarctions (1.8% 
vs 2.9%) and strokes (0.6% vs. 1.0%). 
The differences in va<;eular and all cause 
mortality produced by SK and ASA 
remained significant over the 15 month 
follow-up. 
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TABl.E 1 Plasminogen activation of thrombolytics 
PLASMINOGEN ACTIVATION OF THROMBOLYTICS 
Sk APSA Uk rt-PA rpro-Uk 
Plasma 4 4 3 2 2 
Fibrin 1 1 2 3 4 
Platelet - - - 2 -
Erdothelial cell - - - 2 -
(1- 4 indicated inaeasing ocIwity) 
TABLE 2 Pharmaceutic and phannacokinetic profile of thrombolytics. 
PHARMACEUTIC AND PHARMACOKINETIC PROFILE OF THROMBOLlYlCS 
Sk APSAC Uk rt-PA 
Dosage by I.V. 1.5 million 30 units 2 million 100 gm 
adminisrtation units units (58 million units) 
Infusion time(min) 30-60 5 20-90 180 
Plasma elimination 
half-life (min) 23 90 16 5 
Heparin infusion 
received 0 0 0 Yes 
Cost (MIMS JAN 1990) £85 £495 £198 £816 
TABLE 3 Clinical profile of thromboiytics. 
CLINICAL PROFILE OF THROMBOLYTICS 
Sk APSAC Uk rt-PA rPRO-UK 
Reperfusion% 
(patients treated 
within 3 hrs) 65 68 66 70 67 
Time to Reperfusion 
(min) 45+- 45+- 45+- 45+- 45+­
Bleeding complications 
following invasive 
prodedures Yes Yes Yes Yes Yes 
Re-occlusion% 15+- 10+- 10+- 20+- ­
• • 
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Other major studies with streptokinase 
include Gruppo Italiano per 10 studio delta 
streptochinase nell'infarto miocardico­
Gissi (4,5) (11,806 patients). ISAM (6) 
(1,741 patients); Kennedy et al (7) (368 
patients) and White et al (8). The results 
of these trials arc summarized in Table 4. 
r TISSUE PLASMINOGEN 

ACTIVATOR (rtPA) 

ASSET. (ANGLO-SCANDINAVIAN 

sruny OF EARLY 'IHROMBOSIS) 

(10). 
In this study 13,318 patients with 
suspected AMI were admitted to the 
participating hospitals; 8307 (62%) were 
excluded by protocol criteria (Table 5). 
The remainder received either rtPA plus 
heparin or placebo plus heparin. The 
fatality at one month was 245/2253 (9.8%) 
in patients given placebo and 183/2330 
(7.3 % ) in those given rt-P A (26% 
reduction). Adverse effects included a 
slight excess of major bleeds (dermed as 
bleeding from the gut or urinary tract, but 
not necessarily requiring transfusion) in 
the group given rt-PA, and an increase 
also in minor bleeds mainly from 
venepuncture sites. Other studies include 
the ECSG (European Co-DpCrative Study 
Group for slreptokina..<e treatment in acute 
myocardial infarction) study (11). 
ANISOYIATED DERIVATIVE OF 
THE LYS-PIASMINOGEN 
STREPTOKINASE COMPLEX 
(APSAC) 
AIMS (APSAC in myocardial infarction 
study) (12). This study investigated 1004 
patients in a randomizcd double blind, 
placebo controlled trial. Criteria for 
inclusion included AMI onset within 6 
hours, major symptoms of at least 30 min 
duration; age, 70 years or under, and no 
contraindications to thrombolytic therapy. 
The results indicated that 32/502 (6.4%) 
of patients died following APSAC 
compared with 61/502 (12.2%) following 
placebo. This represented a reduction of 
47.5% in mortality. This trial was 
tenninated; the estimated 1 year mortality 
rates were 10.8% on APSAC and 19.4% 
on placebo (a 43.5% reduction). 
COMPARATIVE STUDIES 
A number of smaller studies have 
compared SK and rtPA on the early 
mortality mte in patients with AMI. The 
overall figures indicated that 36/443 
weighed linear regression 
%= -9.5 *DOT + 93.0 
p=0.0001
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Figure 5 Relationship between reperjusion and delay in administration of streptokinase. (Permission 
from Boissal). 
patients on streptokanse died compared 
with 24/442 on rtPA (13) (14) (15) (16). 
Problems with thrombolytics 
1. With thromoblytics, bleeding 
complications are related more to the 
presence of an underlying va'lCular injury 
and of superimposed anti-coagulant 
thempy than to the hemostatic defect. 
The incidence as mentioned above appears 
to be much the same for all compounds. 
Other in-hospital complications are shown 
in Table 6. Other problems include 
coagulation defects and rethrombosis. It 
is suggested that coagulation defects are 
more common with SK, APSAC and UK 
rather than rt-PA and rPro-UK. Platelet 
defects with rt-PA have also been reported 
with activation of thrombospendin-bound, 
platelet-bound and endothelial cell-bound 
pla"minogen (1). 
2. Exclusion criteria, e.g. the ASSET 
study excluded 61% of patients. The 
overall monaity mte in this group was 
13.1 % (17.1 % in patients with myocardial 
infarction), Table 5. While this was greater 
in the placebo group (9.8%) for those 
patients included in the study, onc wonders 
if some of the exluded patients could 
have benefited. 
3. Adjuvant Thempy Heparin ha" been 
administered concurrently with rt-PA and 
rpro-UK with the aim of enhancing their 
action and reducing the incidence of 
rethrombosis. However, its use in this 
situation remains open for discussion (1). 
It is more likely that aspirin will be used; 
with the thrombolytic agent acting on the 
erythrocyte rich whole blood clot and 
aspirin action on the platelet risk 
thrombosis. 
4. Time of thempy after onset of symptoms 
The clinical outcome with thrombolytics 
appears to depend on the time of onset of 
symptoms to when the patient receives 
thempy. The relative efficacy of rtPA and 
SK fulls from 81% and 55% and 42% 
respectively, when thempy is less than 3 
hours compared to 3-6 hours. A 
curvilinear relationship between risk 
reducton and delay of treatment has been 
demonstrated (Figure 5) (18). This had 
led to calls for the use of i.v. thrombolytics 
outside hospital; the risks associated with 
this still have to be assessed. However, 
the AIMS study and the IS1S-2 study 
have confirmed significant reductions in 
mortality well beyond the period of 
demonstr'dble improvement in myocardial 
function attributable to thrombolytic 
therapy (the mechanisms are unknown). 
THROMOLYTIC THERAPY IN 
THE TREATMENT OF ACUfE 
MYOCARDIAL INFARCTION IN 
MALTA 
Thrombolytic Therapy in the treatment of 
Acute Myocardial Infarction was first 
ll.'>ed in Malta in March, 1989. The 
--- --
--
--- ---- -
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TABLE 4 Major placebo conlrol/eLi clinical trials with inlravenous thrombolytic therapy in acute myocardial infarction. 
Major placebo controlleld clinical trials with intravenous thrombolytic therapy in aOJte myocardial infarction 
-
Study 	 Patient AdjunctiveTherapy Major Bleeding(%) Neurological Event Rate (%) Early Mortality Rate (%) 

Number Aspirin Heparin Plaoebo Act'rve Defin~ion Plaoebo Active En~int Placebo Act'rve 

A. Streptokinase 
-	
- - - - ------- -- - ~- - - . - - - --------- - ------- ------- - ----,.. _-- -
- --­
GISSI (4) (5) 	 11 ,806 14% 21 % ? 0.3 Stroke 0.9 1.1 21d 13.0 10.7 0.0002 
SK-CVA 0.2 

ISAM (6) 1,741 + + ? 0.8 ICB 0 0.5 21d 7.1 6.3 NS 

WWASH (7) 368 ? + (0.7) (13) ICB 0 0.5 14d 9.7 6.3 NS 

N.ZEALAND (8) 219 + + 0 1 ICB 0 0 30d 12.9 2'.5 0.012 

ISIS-2 (3) 17,187 +/- - 0.2 0.6 Stroke 0.9 0.8 35d 11.7 8.9 0.0001 

SK-ICB 	 0.1-0.2 
B. rt-PA 
. --- - ------------------- - ------- - - ---- --- ----- -- - - ---- - - --­
ECSG (19) 721 + + 1.9 3.7 Stroke 0.5 2.0 14d 5.7 2.8 0.053 
ICB ? 1.4 
ASSET (10) 5,111 - +(24hr) 0.4 1.4 Stroke 1.0 <1.1< 30d 9.8 7.2 0'(XXl2 
C. APSAC 
-------- ---- --- ------ ------------_._ - ------------- ---- --- --- - --_ .. __._-	
- ---- --- -
-
.---­
AIMS (12) 1,004 ? + ? ? Stroke 1.0 0.4 3)d 12.2 6.4 0.0016 
Abbreviations: *ICB: intracerebral bleedi~ ; CVA: cerebrovasrular accident; SK-CVA: associated with streptokinase therapy; Sk-ICB: ICB 

associated with SK therapy; rt-PA ICB: ICB associated with rt-PA therapy. 

Collen and Gold (9) 

TABLE 5 ASSEr mortality in excluded patient,. 	 TABLE 6 In.hospital complication other than strokes. 
Reason % Exdusion % Dead rt-PA Placebo 
n % n % 
durauon symptoms > 5 hrs 73.5 10.6 Recurrent M I 97 (3.9) 111 (4.5) 
age > 75 yrs 8.3 26.2 VentriOJlar arrhythmias (day 1) 149 (5.8) 107 (4.3) 
recent haemorhage, ulcer Ventricular fibrillation 94 (3.7) 120 (4.8) 
bleeding diathesis 	 5.9 12.1 Asystole 100 (3.9) 124 (5.0)
other serious disease 5.4 13.5 Pulmonary embolism 11 (0.4) 15 (0.6)
refused consent 	 4.3 8.0 Other embolism 12 (0.4) 19 (0.8)
receiving warfarin 	 4.2 10.0 Cardiogenic shock 96 (3.8) 131 (5.2)emergency CPR 	 4.1 28.7 
Heart failure 	 453 (17.9) 466 (18.6)recent stroke, trauma or surgery 3.6 14.3 

lives away 3.6 7.4 

high systolic BP 2.2 3.8 

Hampton (17)proliferative retinopathy 1.5 18.5 
pregnancy 	 0.3 3.6 
_._--
Hampton (17) 
TABLE 7 Cost per administration of thrombolytic agent. 
THROMBOLYTIC AGENT 	 COST PER ADMINISTARTION IN LM* 
Streptokinase 33 
Urokinase 158 
APSAC 275 
rt-PA 453 
* Source: last tender for SK & UK Mims Jan. 1990 for APSAC & rt-PA 
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Thrombolytic agent used then was 
Streptokinase. 
According to the policy (19) adopted by 
the Department of Medicine, St Luke's 
Hospital, the indications for using 
thrombolytic therapy in AMI are as 
follows:­
- Age: < 65 years (the age limit is only a 
guideline, the decision is at the 
discretion of the admitting consultant) 
- Diagnosis: (a) typical chest pain > 30 
minutes 
(b) ECG: ST> Imm in 2 or more limb 
leads 
> 2mm in 2 or more precordial leads 
- Time factor: treatment must be initiated 
within six hours of onset of the pain. 
- Negative test to nitrates: no 
modification of ST elevation five 
minutes after the administration of 
sublingual GlN. 
To date (April 1990), a total of about 150 
patients suffering from AMI were treated 
with Streptokinase. Urokinase has been 
recently made available in St Luke's 
Hospital. The use of Urokinase in the 
treatment of AMI is being restricted to 
those patients who suffer a further AMI 
after 8 days to within 6 months following 
the previous one. At prcsent,it is estimated 
that about 12 patients will benefit from 
the use of Urokinase per year. 
Streptokinase is administered in a dose of 
1.5 million units over 45 minutes in 60mls 
of 5% dextrose. It is used in conjunction 
with other therapy as follows:­
- Hydrocortisone 200mg IV 
- +/- Lignocaine lOOmg IV bolus 
- +/-B Blockers (early) 
- Heparin 1000 uniWhour, started one to 
two hours after the end of Streptokinase 
infusion. It is continued for six days, 
the dose being adjusted to keep APIT 
at l.5 - 2 x normal value. 
- Aspirin 75mg daily 
If reinfarction occurs within seven days 
of the use of Streptokinase, it may be used 
again together with a high dose of 
corticosterOids. 
UrOkinase in administered in a dose of l.5 
million unit'> over 30 - 40 minutes in the 
same way as Streptokinase with the 
exception of corticosteriods which are 
not required with Urokinase. 
Although the Medical Department is well 
aware of the other thrombolytic agent,> 
now on the market, ego APSAC and rt­
P A, and the possible advantages they 
offer, the cost involved must also be 
considered (fable 7). 
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